Journal of Alzheimer's disease : JAD

Links Between Tau Protein in Brain Areas and Daily Functioning and Apathy in Mild Cognitive Impairment and Alzheimer's Disease

Updated

Abstract

Forty participants (24 with mild cognitive impairment, 16 with Alzheimer's dementia) underwent evaluations revealing that IADL impairment is associated with greater tau in multiple brain regions.

  • IADL impairment was linked to increased tau levels in regions such as the medial orbitofrontal and entorhinal cortex.
  • The interaction between tau and amyloid was associated with IADL impairment but not with apathy in the anterior cingulate region.
  • Similar associations for IADL were observed in whole brain analyses.
  • Apathy was associated with tau in small clusters within the right anterior cingulate and dorsolateral prefrontal cortices, particularly in individuals with higher amyloid levels.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

Conflicts of Interest/Disclosure Statement. The authors have received research salary support from Eisai Inc. (GAM, NJD), Eli Lilly and Company (GAM, KAJ, NJD, RAS), Janssen Alzheimer Immunotherapy (GAM, RAS), Novartis (GAM), and Avid Radiopharmaceuticals (KAJ). Additionally, DMR has served as a consultant for Eli Lilly, Neurotrack, and Lundbeck, GAM has served as a consultant for Grifols Shared Services North America, Inc. and Pfizer, KAJ has served as a consultant for Eli Lilly, Novartis, Janssen, Roche, Piramal, GE Healthcare, Siemens, ISIS Pharma, AZTherapy, and Biogen, NJD has served as a consultant for Avanir, and RAS has served as a consultant for AbbVie, Biogen, Bracket, Genentech, Lundbeck, Merck, Pfizer, Roche, and Sanofi. NJD’s spouse is employed by Alkermes.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free